Department of Neurosurgery, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.
F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA 02115, USA.
Int J Mol Sci. 2022 Sep 5;23(17):10179. doi: 10.3390/ijms231710179.
The optic nerve, like most pathways in the mature central nervous system, cannot regenerate if injured, and within days, retinal ganglion cells (RGCs), the neurons that extend axons through the optic nerve, begin to die. Thus, there are few clinical options to improve vision after traumatic or ischemic optic nerve injury or in neurodegenerative diseases such as glaucoma, dominant optic neuropathy, or optic pathway gliomas. Research over the past two decades has identified several strategies to enable RGCs to regenerate axons the entire length of the optic nerve, in some cases leading to modest reinnervation of di- and mesencephalic visual relay centers. This review primarily focuses on the role of the innate immune system in improving RGC survival and axon regeneration, and its synergy with manipulations of signal transduction pathways, transcription factors, and cell-extrinsic suppressors of axon growth. Research in this field provides hope that clinically effective strategies to improve vision in patients with currently untreatable losses could become a reality in 5-10 years.
视神经,与成熟中枢神经系统中的大多数通路一样,如果受伤就无法再生,并且在数天内,视网膜神经节细胞(RGC),即通过视神经延伸轴突的神经元,开始死亡。因此,在创伤性或缺血性视神经损伤或神经退行性疾病(如青光眼、显性视神经病变或视神经胶质瘤)后,改善视力的临床选择很少。过去二十年来的研究已经确定了几种策略,可以使 RGC 再生视神经的全长轴突,在某些情况下,导致中脑和间脑视觉中继中心的适度再支配。这篇综述主要关注固有免疫系统在提高 RGC 存活和轴突再生中的作用,及其与信号转导通路、转录因子和轴突生长的细胞外抑制因子的操纵的协同作用。该领域的研究为在 5-10 年内为目前无法治疗的患者提供改善视力的临床有效策略提供了希望。